-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 TCbohdQiJ6NGM/2glJd8zwDDg1fWbXATm0Rho7xSieLZUInRxXMfOCT3PxmawI1V
 aexS5fMBX0vHHUNuZZiFkA==

<SEC-DOCUMENT>0001193125-05-070447.txt : 20050405
<SEC-HEADER>0001193125-05-070447.hdr.sgml : 20050405
<ACCEPTANCE-DATETIME>20050405172451
ACCESSION NUMBER:		0001193125-05-070447
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20050405
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20050405
DATE AS OF CHANGE:		20050405

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CRYO CELL INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000862692
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-SERVICES, NEC [8900]
		IRS NUMBER:				223023093
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23386
		FILM NUMBER:		05735010

	BUSINESS ADDRESS:	
		STREET 1:		3165 MCMULLEN BOOTH RD
		STREET 2:		BLDG B
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33761
		BUSINESS PHONE:		7277230333

	MAIL ADDRESS:	
		STREET 1:		3165 MCMULLEN BOOTH RD
		STREET 2:		BLDG. B
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33761
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE
COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="3"><B>Pursuant to Section 13 or 15(d) of </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>the Securities Exchange Act of 1934 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Date of Report (Date of earliest event reported): April 5, 2005
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>CRYO-CELL International, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact
name of registrant as specified in its charter) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>0-23386</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>22-3023093</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>700 Brooker Creek Blvd., Suite 1800, Oldsmar, FL</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>34677</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Registrant&#146;s
telephone number, including area code: (813) 749-2100 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>Not applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P><HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left">

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item 2.02. Results of Operations and Financial Condition. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The information in this Item is furnished to, but not filed with, the
Securities and Exchange Commission (the &#147;Commission&#148;) solely under Item 12 of Form 8-K, &#147;Results of Operations and Financial Condition.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On April 5 2005, CRYO-CELL International, Inc. issued a press release that included financial information for the three months ended February 28, 2005. A
copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>Item 9.01. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Exhibits</U><B></B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">99.1&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Press Release dated April 5, 2005. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">-2- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">CRYO-CELL INTERNATIONAL, INC.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">(Registrant)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Date: April 5, 2005</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">/s/ Jill M. Taymans</FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Jill M. Taymans</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Vice President, Finance</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">-3- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><U>EXHIBIT INDEX </U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>EXHIBIT</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>NUMBER</B></FONT></P><HR WIDTH="56"
SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>EXHIBIT</B></FONT></P><HR WIDTH="53" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release dated April 5, 2005.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">-4- </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g49235imge_001.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>For Immediate Release</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><B>Contact:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><B>Todd Atenhan</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;813-749-2100</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">813-855-4745 (Fax)</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><U>investor.relations@cryo-cell.com</U></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>CRYO-CELL
INTERNATIONAL, INC. REPORTS RESULTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>FOR FIRST QUARTER 2005 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Company Reports Net Income, Increased Revenues, and Strong Cash Position </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><I>SOLID FINANCIAL PERFORMANCE CONTINUES AS COMPANY PROCEEDS WITH
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><I>STRATEGIC PLAN </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Oldsmar, FL &#150; April 5, 2005 </B>- CRYO-CELL International, Inc. (OTC Bulletin Board Symbol: CCEL) (the &#147;Company&#148;) today announced consolidated revenues
of approximately $3.3 million for the first quarter ended February 28, 2005, compared to approximately $2.6 million for the first quarter ended February 29, 2004. The 27% revenue increase over the same 2004 period is primarily attributable to the
effects of successfully implemented price increases during 2003 and 2004 for newly enrolling clients, as well as the overall increase in customer base over the prior year. These price increases began to have a positive impact on revenues in the
third quarter 2003 and have continued through the first quarter of 2005. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Net income in the first quarter of 2005 was approximately $179,000, or $.02 per common share &#150; basic, compared to net income of approximately $214,000, or $.02 per common share &#150; basic, in the first quarter
2004. The Company&#146;s operating income in the first quarter of 2005 was approximately $267,000 compared to operating income of approximately $272,000 in the first quarter 2004. The slight 2% decrease in operating income year-over-year is
attributable to a 36% increase in cost of sales and a 32% increase in marketing, general and administrative expenses in the 2005 period versus the 2004 period, partially offset by a 27% increase in revenue, as described earlier. The increase in
expenses is a result of the Company&#146;s strategic plan to build the infrastructure to enhance existing production procedures and quality systems in the processing of cord blood specimens at the Company&#146;s new state-of-the-art, current Good
Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility in Oldsmar, Florida. The Company also deployed a new customer database, new network infrastructure and implemented plans to expand sales and marketing initiatives.
Despite the investments in the new facility, operating infrastructure and information systems, the Company&#146;s cash increased approximately $377,000 over the fourth quarter 2004. As of February 28, 2005, the Company had approximately $6.3 million
in available cash, cash equivalents, marketable securities and other investments, which represent a 75% increase over the first quarter of 2004, and no long-term debt. First quarter 2005 enrollments, an indicator of future revenue levels, increased
approximately 20% over fourth quarter 2004 levels. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company
also recognized approximately $105,000 in licensee income in the first quarter of 2005, compared to approximately $77,000 in the first quarter 2004. Licensee income principally consisted of income recognized from royalty income earned on the
subsequent processing and storage of specimens in geographic areas where the Company has licensing agreements and from the sale of sub-licenses by licensees. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">&#147;We are pleased that CRYO-CELL has reported a profitable first quarter of 2005. The Company continues to make significant progress in accordance with
the stated priorities of our strategic plan to accelerate growth and to achieve industry-leading technological and operational excellence, with a keen focus on process automation.&#148; said Mercedes Walton, CRYO-CELL&#146;s Chairman and interim
Chief Executive Officer. &#147;The Company&#146;s substantial investment in our new state-of-the-art facility, advanced systems and operational infrastructure has established CRYO-CELL in a formidable competitive position, well ahead of emerging
regulatory standards that will have industry-wide impact.&#148; </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g49235imge_001.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">&#147;Notwithstanding expected
quarterly fluctuations in net income due to increased expense associated with operating a cGMP/cGTP-compliant facility, in addition to planned increases in marketing and sales spending,&#148; Ms. Walton continued, &#147;we anticipate that our
strategic investment in our business, combined with our sustainable success in operational execution, will continue to impact unit growth and profitability.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">About CRYO-CELL International, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Based in Oldsmar, Florida, CRYO-CELL is the world&#146;s largest U-Cord&reg; stem cell banking firm, offering high-quality cord blood preservation exclusively for the
benefit of newborn babies and possibly other members of their family. With over 75,000 clients, CRYO-CELL is accredited by the American Association of Blood Banks (AABB) and operates in a newly constructed state-of-the-art current Good Manufacturing
Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">CRYO-CELL is
a publicly traded company. OTC Bulletin Board Symbol ... CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit <U>www.CRYO-CELL.com</U>. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Forward-Looking Statement </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Statements wherein the terms &#147;believes&#148;, &#147;intends&#148;, &#147;projects&#148; or &#147;expects&#148; as used are intended to reflect &#147;forward-looking
statements&#148; of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or
paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include any adverse effect or limitations caused by recent increases in government regulation of stem cell storage facilities; any increased
competition in our business; any decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease in the number of people paying annual storage fees; any adverse impacts on our revenue or operating margins
due to the costs associated with increased growth in our business, including the possibility of unanticipated costs relating to the operation of our new facility; any technological breakthrough or medical breakthrough that would render the
Company&#146;s business of stem cell preservation obsolete; any material failure or malfunction in our storage facilities; any natural disaster such as a tornado, other disaster (fire) or act of terrorism that adversely affects stored specimens; the
costs associated with defending or prosecuting litigation matters and any material adverse result from such matters; decreases in asset valuations; any continued negative effect from adverse publicity in the past year regarding the Company&#146;s
business operations; any negative consequences resulting from deriving, shipping and storing specimens at a second location; and other risks and uncertainties. The foregoing list is not exhaustive, and the Company disclaims any obligations to
subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements. Readers should carefully review the risk factors described in other documents the Company files from time to time with the
Securities and Exchange Commission, including the most recent Annual Report on Form 10-KSB, Quarterly Reports on Form 10-QSB and any Current Reports on Form 8-K filed by the Company. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g49235imge_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g49235imge_001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`00*H`P$1``(1`0,1`?_$`*4``0`!!`,!`0``````
M```````)!@<("@$"!0,$`0$``P$!`````````````````0,$`@40```&`@$"
M`P8$`@8"#0T```$"`P0%!@<(`!$)(1(3,1355Y<802(5"E$687&!,B,7D3?P
ML<%2,U:6UG>W6!D:T>&S)'1%-D9VMB=X.1$!``(!`P(&`P````````````$"
M`Q$Q,A(305%Q@3,$\"%B_]H`#`,!``(1`Q$`/P"<;]P1W4=F.U_5-6IS7.)Q
MC,/<RVG*$+;$LF0$M/((,Z="521BU(C]*G80[9<[B;4!83BH!R@'0`Z=>)::
MUK;V:S__`(LCN>_\2M5_I]</^?O(=]JCZH?NP>Z*[6*V94'6%\Z."ABM6&-+
MP^=B5+KZAP:M+RLX,0@E$#&`HE`0\1#@[5'Q#]V5W.Q#J%,U6'Q$H@&/[AYB
MF*/0Y#%_G[S`8ANH"`AU`0$!]@\':HY_\61W/?\`B5JQ]/KC_P`_>#M4;.G[
M?GNB[)=T#'>S%JV+B,9P\GB#(5"K%8)C2ORD"T7C;)5Y";?FEB2\[.J.G!'3
M0H$,04@*41#H/MY+-DB*WTC9L.&,4O3S#TZ]?P$?8'4?8'X`'#@*<#>(=1#P
M\>@]!Z_PZAP."J)GZ^4X#TZ]0#VATZ=?#V^'7@<B<H!YO$0Z`/@`]>@]>G0.
MG4>O3@<^8OCXAX>W\.GM]O\`#V<#J*A`\>OAU*'4`$0ZF]GB`"'0>!R)@`.H
M]?#V^`^']?AX<#J59,_]TW7\PE]AO[P=>H>(>T.G`[><OM'J'B)?$!#J(!U\
M`$/$.@<#MP'`ZB<H`(]>O3V]/$?ZN@=1ZCP.>H#X_P!OXA_M\#J50AO8/7^P
M0_$2_B`?B7@/.7H(]>H!UZ]/PZ#Y1'^HH^W^'``H01Z`(B/]`#X^!1\/#Q\#
M`/\`5P.P&*/X_AUZ?CT_CT]O`ZBH0H"(F#H'7^GV`(CTZ=>O3IP.WF#^/X`/
M]0#[.O\`#KP.>`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X
M#@.`X'0JA3`82^80*;RCT*;^\`]!`/#QZ#P/F+E$.GY_$W3H4`$3?F."8?E`
M!,`"H/0!]G7PX'8RZ)"B<RA`(`G`Q^H>4OIF$BGF,'Y2@F8.ANO]T?;P/RLY
M6,D!6"/D6+\6YBE<`R=(._0,</,0JWNYU/2,<OB`&Z"(>S@?L]4GC^;V&`HC
MT'H`C[/'IT_W.!YTE-P\,W!Y,2D?%,Q6;MP>23QNQ:"X=K$;M6X.72B2(KN5
MU2D3)YO,<Y@`H"(AP/1,H0O]X>G0!$>H#X`'B(CX>`=/X\#CU2=2AU$1-[.@
M#_3_`$>'3IX_UA_'@>>SG(60<NV<?+1K]XP4])\T9/FKMRR4$YB>1VW;JJ*M
MC><HAT.!?$.!Z/J$Z"/7V!U]@^SH`_[O`\XLW#&DQA"RL<,T#+]3-#@\;C*E
MC?5!#]0-'`I[X#'UQ\GK>3T_/^7KU\.!]%I>*;N$VCB28-W:QDR(M5WC=%PL
M941*D5)!10JJAE#`(%Z`/F_#@=&TU$/7TA&,Y2/=R<2#896-;/&R[^,]\3,L
MT"09I*'<LC.DB"9,%2E%0H")>H`/`Y=S,0P=1S%]*QS)[+N%&D2S=O6S9U*.
MDD%'*K:.;K*D5>N$FR1E#$2`QBD*)A#H`CP/2X#@><_F(F*,@63E(Z.,Y$X-
MP?O6S,5Q3\OJ`C[PJGZHD\X=0+U$.H=?;P/SEL4`=BZE"3<2>,8E4.]D22+0
M[!F1$OG5.Z>E6%LV*D3\QA.<H%#Q'H'`_>V?,WC5!ZT<H.F3E))=J[;J%7;.
MD%TRJHKMETA,DN@LF8#$.01*8!`0$>O`X0?LG0',V=(.`376:J>@J142.VXG
M!PT,!!,)73<Q!!1,?SD$!`P!P/J*Z1>GF,)>O00`2F`1`?8/3IU\1\/Z^!\P
M?,Q<"S!RB9V"*;GW8JA3+^[*J"DFY!$!%06QU2B4%.GD\P"'7J'3@??U"]/-
MU'I_'RFZ>P1]O3IT\/\`3P/PIR\6JY>LDW[,[R-3;*R#0CA$SEBD\*H=FH\;
M@?UFJ;LB1C)F4`H'*41#J`#P/V^LGYA)YOS!Y>H=!ZAYO8'L]H\#OU#KT_VN
MH_Q]O\/9_IX'S,LF7^\8"_E$WCX?E#R@80#VB!1.`"/L`1Z<#L4Y3_W1Z^T/
M[2CT,`_P,4?`0'Q`>!I5_O(?_@#0`H`8PC?L]@4"].HB-6QUX#_`!_#V^/0/
MQXEIP3K.D^,M%DQ%"E(*J:B?JI%73!0AB^=!03E353'H(+)'%,P`<G4HB40#
MQ`>0TWK%9TCR;>O[7.\CAZ/V7NDII-F'.<9;IRM0,/G[$-#K.2I2B/:[$+N9
M[%,_"R4]&6:"9SB4PVD6Z[5,Z3E0PE6\"E,1#/EF8B-)\4+O>U>*2_<@SM;_
M`+8[!J0TNY*A8HG$MNCZW#6YPP-76D<?(=CK=4DY:)KTAD)U'*OSM06,HF"@
M&/YC&,/"[#7KK^Y15\(;XW[.(>F%=[A`.HAF/$0@'4`Z_P#X^FO#J/@'7B&3
M+SE+[W#>X/FF'V8POVS="T*L^W,SJP4MEVR9;8T;%2=5<*M2&<2>3K'7"G*G
M8;2[8(+'B8YP8B!C`D*@']=,HRK7QB^V'&N:H12\[L[_`-ORRJR,=_F9MLU;
M:9*MYLQ#BO(5W'M2*QQ77XM%V83(1@0[ALFF`)G]7\PF"V^IN)]RKM0=G]4=
MN]F,R/K1@_.,,WPCM7BIO$8JR-D/"UAHT-::4[GI=E7WU:L,Y%2;]XQGDBM#
M)K.&8%6\!`.!'7VA:MMQOWJ7G?*.2.XWM]`YFI&S.;L)XYM=>G\?DIT+'8T5
MAVM:E+%CEUCY2%N`O7;T3R"3DQ/73ZD1.AU\P!6.I&8]W^Z=IOGRG);+VW6/
M?32'.F3\`O,IX71@F&(<V6VLI,U:]-7VBST).,EH:=2:&0729*-A8*J&<I")
M3^EP+S=@S9O)6>L49UH^T.9,P7'=_`N5)?&FR>-LM3$`HWH[Z*EIA*K3N.*S
M"UFOEBZI9(PXH.%3^]`LZ9>;SE*<GF"Z&)J?F387?3-F3:'N1LS#Z0X#G_Y/
MDJ@-KIZU,RILI#2:TOD6`I\VM2QFV."<41BC:&D4BO3%>3GO+=)<I&BHF"FL
M#9GS)W=LE9CMV,<RWO7?MVX:R'.8;I$[AAXVJV:=M\@4XQ&U[MQLD.V#^2Q[
MA>`D%`9Q[>$(A)2YQ,JJ[2('I<#UMH]&ML=;*#/Y[[;FV6P[S*N.(Y[;Y#6S
M8_)D_L)A+/$-#I>_S5-,VR"O(VVEVZ68(*ECW\7)(@+@2IB0H'\Y0R_[8W<)
MH'<HU7J.P=/B3U&RIOG]*R[C9VX]YDL;Y0KR3?\`F&N+J"!%E8Y4%R.F"ZA"
M&69KI]0`X'``D+.82^P2@'3\0$?'J'C_`'BAT`.OMZ?U\#7LA-MMBNZQMUFW
M7[3O+$MKAHOJC/A0\][2T!G"O\PYTRP"BQ'N,,$STVSF(.AUB&*U.+RP)M7#
M\Q``Z`I@LEU#)+-W;;RA#8UL<[IIN_N+BO9"#C'<S1YO(^>+/G#'-VL<>U,[
M:P&3<?9.&P5^1@9]R0$%E6B3)=J*GJ)CT+Y!##[?K)6V+CLO1^_+#.^;M9=L
M,3ZX4FZW:HX_7BZS0YN^GL%?A+Y%6S'L]`28@!Y%VZ*R42504;I@F`=2"("&
M4.IFJ69,U:9:^9(O'<,WA1RSEG"%#R+/VV`ON/6<:QG[U58ZQG"*JBV+W<.2
M,AU94$DD%/.=1-/JH<QA$>!9G:BM[JXC[-TQEFV;5YSQON)JSA?(=SG;W!/J
M89'*,[6[+)*1Z^2ZZZKLS#2[6<JK1OZ0-SMA9"X$P=1+TX&5_9V8Y9M^DV"M
MC,V;&YGSUD?8C%-/R%929(D:O_*U4D)A)=^9A0Z[7*S")0C)-%P5$XJK.CK`
MF!Q$!'IP*$[XS_-V(M#LW[6Z\[(99P1D[76E%ML.QIKNL.:1<TEK+!Q\A'W6
MMV2N2Z<DN9B^.5LX360,@<`_O`(\"^W:TK>1G6G>#<R9:V"S#GW(.>L2XORM
M9Y/*,I67,979BT5-G-O8JBPU:K5?9UZ#!64\@I&%P<_I%,)^O7J$D/`<!P'`
M<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<"+;N':L83V?D,8
M46XTVP6;+=[/,8_H$['7G)%5CL4T4P(SF5LH+,:7:ZY$*RM>@2%2CEGI5SJS
M+I@B4/3%4H!!OL!CS>.J;(YKIVLT;E=GL;6MB<BQ&"'R*]S>4V.[>\5VWY"N
M8ZC&DX\6/6%&Y<]-VI6Q55C22ES#UC>97J<0D5[/["WQCK:.2EHS(49K`;#^
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MDFU_9&S?E>`?1;+<?+^);1*8OIF)Z)8,0WNDMF<XE$6NC,$[?89:05R:^K,;
M)%B7Y08"#IVV!,GF`JI@\7+.?L%ZYZHQN7-!\,K,=HZ)@6DUZ#)+X)RJZ=U*
ML6#(V*J]<JGG=B@U@)65R`9V]=.F[>15=2AW4<\<@;T`644#Q+EW&>X]CB6V
MMKCK%./<A6G6ZK)HPM5K^#L^,IK+=:>L\;.V.T]#4C6]DJDQCM!O99Y=W6&D
MR]F`)$$;)%%R"W4,:9;;;8BA[R8LV6?U,ES#)FH6&</94SYB+`N8)FB4G'\_
MN/?'#.\$QC:86L7.PS2=,5B@E4FYBA$IO3216ZS%'TA"H>]?3)7(.W55/5&:
MB:\EVP-OX)&UJXGR-D%FMD:4GZ!,XJKE9=4M)N6MYEL2,=(EJS_JL^C%CG62
M;*=`3$/&QAF/=3`=YVVV+PWKE;%YJ0>=J,,\X,R%5[-<,K2U&E=98#'>3V]%
MO!E*W%7++.+;S(MTYYT8KU)3TW2CDB2J8E`*AR1L;L7=.X!J(IL[29&$5TLV
MZS*PEX;'N!LE/0L>.G.C5UETM@(VWM0LL9)U*]W65<P41$,#G,5TS0374,Z.
M`<#9ZQO?83*=!IN2*VA--J]>ZS"VR$;62"E*Q84(J?CT))BC.5R;;,YB"E4V
M[@H+M'*2:Z"H"0Y0$.!6W`AZ[X^*JG=.W3M5:1H"]VR_#8&O-1PZI$0$U:+E
M'V&Y.H,3M*-%P;=])-K#+.(9N4KEHB#HI4O*"A2"8!"-S,^6,FQU6W+U0Q7@
MZBXTP'8]-)J[HQ:&'LQOKKLN_P`D:AOQF,E8TFJQ5UZ!"V&KY.AXZN/H9^=J
MX$R"BAD?>G*(B$FVBN8<SVG5K*-.:QT>-BU^P9ABFX;A0QMD^D6`LW]IE%L*
M$7;92_L6L%>)K^?72B)G5?*9BT`ONBP>\I*=0@GS4USH^?Z!6O$37*%FK;#4
MC4:U7Z$28W<]OR=D^T[/UNRYK?:OW*N-WD;4-GX6="2_S"-9TU$WE64%L`(@
M114H2S8QLE1J6QW>8#)5P=TC%4UDO6D]6LF5C9,#%S=:<Q?%5JT*U]X=_$I.
M:FIDQV9I*-X5^U9`X5.151),XFX&.6@L;F'&UFT]I`QDB$C&[S;[X_C+DR5M
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M(DZ<V02?HY+&X:`9JO(`D(G,H`]`C'_>2!UQ_H`/Y?"_9[$/-U\/+5L=&$0Z
M=!\Q2@(A_3Q+3@B8G6=H4C@[LNT7N;]B+2FZ40T+2-P<=X_R>?&F1'2*3*-N
M\4.8<B.QQ9DAPW1,LZ@'BW4(V0,55>'<B`D`6YUDQ2LRY8C)_.D,I/VG.,<@
M85QEW"<3Y5J$S0,E8_V<J-:N5/L#064Q!2\=C=LBHV<I]3$504(`*-UTC'0<
M-SD52,8ARB,*,EZWF-&N;^YK`![Q&>?`/]7&`NO]F.&@!_HZ\EL^KQ_/)`OR
M'#?'_9P_ZEM[?^F/$7_5]-<0R9><KR=LU?\`7OW(7>,E<A=5K[`4V%AZ#^I*
M',[:X^0EZ,R;DB4UBD,5J:!;QP_DZE]-4.G@(\E6VT">7TP$O02^7J'0/:7V
MA_:(>W@=4SIB(D)T#R^TH```'7H;\/#J/FZ_V\#1"T8S[W"-6.T]N=GO4Z&P
MS8L8T7>/9B0R>5[7;7.;`T:L?S)`-KMD;'<<M*M\;VQ6JQ+@CQNQD4DP;@W4
M54%9(IB<#:'[1.%=5,2Z3XWLFHMHG,CX_P`\@ZSM8LNW-XUD,A95O]\$KJV6
MB^N&::35I9&\FB=BLP1*"$<9J+<G4""(A#EWH\.WG5O?W2S=#4;)"N",K[LY
M$C]#\_OXN-3D&%H@[Z@UC:[D9Q"&.DQ>W&G1`JF9N%!*=)XS8K?F%,X&":#:
M7&\?J=VK]D<<:^Q3F&C\1ZB9=C*,FV5%W-^],J!/JR%B?/50]:2LTJ\7<2;Q
MV<15<OE5%3#YC>(8C_MK?Y?_`.YSU-&"!!0XAE/]:52Z^?\`F`,I6\LF9R8P
M`<71A*F!^OM\.GATX$[9_$Y`$.H>(]?'J`@)>G3\.@@(]?\`S\#4U[#SNNX/
MW&[\*;JR0=(UQH&W+,4)FP2;"O4JN3JUDR21^)I:36:QL<F@P<M$%#'4(0`]
M$O\`O>!/;F3:["%RPQF^"P5L'AJ^9<'!^89.BU2B90I%HMLC8(7'=CE6!XF#
MA)M[)NUF3EH50_D2'TRE$3=`X$1?[4=K7R=I^#DHST%K%-Y_S7(7UT!RG>KV
M8):,11/(FZBH*PP23,2^;^\4P&#^]P-E7H'MZ!U'V^'M]O\`Y>!#YW]E2?\`
M<[;ZFZ=0+AQL)P\H"/D&[U,?R]1`HG$.H%'KT`P@(^'7@8"1H]V]MVNM8'&-
M9G4Z.Q<AB+4O]1_RRCLXCL6?#*CC&C>93K2KU=>H(74M06,#\Q$A1%+W@$/*
M(D'@2F]Y0Q?^ZNWV`HAU#6C)'L'Q`/TDP#_2'CP.W9J$1[5FA`B/4?MGQKXC
MX_\`N<G`MOW[!*;L][\EZ@/3"2O4/`>G6U5GIU#^G@9,=L[_`/G=H[_^J>!_
M^K:N\#-\!`>H`("(=.H=0$0ZAU#KT]G4.!SP'`<!P'`<!P'`<!P'`<!P'`<!
MP'`<!P'`<!P'`<!P'`<!P'`<!P,0M@]O<:Z]WC&.+IB!NU^RME^&R/8,>8VQ
MS#QDG:[%7L31D;.7UY&)3DU`Q[M:*:2;8$(]%=20D%U"D;HJ&`>@9(+6MBA4
ME;@LUF?T]&N*6E2-2AY!Q9/<4HL9<[-.N((JRJTX"!1(#%-,[DR_^&4HFZ!P
M*?QYEBF9+K%7M$$[>L0M=)@,@M:Q:XUU5+W#UBR(>O&O;32)TC.QU=4#)J)*
MIO6Z)TET5$S=#D,`!2.Q^R&*]5<16/.F8Y*;B<;5%:$2L$U`5B=MSB++8)5G
M"1SQQ&5QC(OTH\TC(HIJ.1("*/J`)S%`>O`M;DC?/7#%.8H[!EOL\TE='"F)
M6TZO'U>8E:U1G&>K+*4["Z-\GFS<S>`/DBSP[EFQ,8#IE42$S@R*8E.(6RBN
MZMI3,U^^VEKDF52B:)`P%I9&=TZR-'63:I<<I2^$*=9<0,56(.\BPMNR]`N*
M_'JL"F]>0*3P*DHFJ8,L<#9[QMLA0PR-BV6<RD$C8[;29MI*1KN$L-6O%"L4
MA5+K2;5!/R)O(:S52Q1CAH[;J!^50GF*)B&*80O3T_V?[/ZN`X#@.`X#I[/Z
M/$/Z/P\/[!X```/``Z!_`/#@.`X&+&SNV=$U6/A9&[5?(-H>Y[S!`X)QVPQ_
M"Q<RZ>9)M4=+2E>B97]5FX1O%L)-M!.O_6C*"DD9+\_E`0'@7=QAD1MDFGQ]
MN)6[92S/W4RU5JE[C6T/;(U>&G)"`<_J#!M(RC0R#A]&'.U70<+(.4#D.F80
M,'`N&1PDKU\HB;RJ`F;\AOR*?E$"FZA^40$0_P!O^'`P;M^X^M>`YZUT;W>0
M:N(?+M+Q2>'HE9(_&T[#YLB9'(47B^KQS-5(LK?7U42//2@""*#1LZ3.JL"B
MIB\#W*1O;K-E.RZYTJI6B9FWVV..KIDS#"CBB6IK`62KX];I.+LWDIF0AT(B
M$G*YZI2.8YVHF[*?I_AB`E$0H21WMU@@\F93:3$+=8*[8.K>-'&1+-9\73M;
M"`PYERY/ZS6+_&S\TQ9DD<:J6Z#4._*@H5TU00]\4:BW("G`NULAM]@K5!*J
MCE)_.?JU\87^=KM>I]6?6NR2]<Q'35KSDNV>X1R0F&#H=.:^]O5C'\_I"0J)
M%3F*3@4K';TX-M^7ZYB.G0.4L@*/:'7LKR.4:UBV>?X3QY4K135+W696]92?
MHLJ]5Y*9JAT7+=GYSOQ3>(`*1?5#H%;ZR[44K:ROV*Y8]H^8ZU4(>7;1D-9L
MKXRG\;1N0FSAN9TG8L<DL0I/;15@(`>5\5!-(QC`!>H\#P\C[G8IQ?9<GUI]
M&WZ[2&(:S59R\L<6TR8R7:F\K=)=I'5NF0-`IZ4O>[39W#5Z20=IQ\>NWC6*
MJ)G*B1EDRF"A:UW#\#W'"MUS=$PV5X"$IV2TL.*U7*>,[/AJZ3N4U%(Q%.G0
MD!D]O5E3N$G$LF#IVJ*;-D1)PHNJ0C98Q`N'!;>T&T;%S.M-:IV8+#;*E'IN
M+SD"'QM.O,'4>1<5Z-L[>KSV7A.A5AMCB-EVOECVJCER*JQ2F`OX!JN?O(_]
M7N@/_P!>[`?_`&CC[B=VO%M/JFQ_;Q%`>S?I/X__`"??_P#KAR'_`$#_``XA
M3FY^T,8^XQW6J_VLNYYKY"9"K$.&MVU>#R*9ZL\1"M0NE7M]5OCVJ4K*SEZS
M0*]L<36H!X#"0:*F44+&`"B`>HW`ARIJ(_N0;/7KMW8,KW2HS<99:I;<.:WV
M2LV*%>(R$//0,QB^.>Q<Q%OFQCMW;"0:+%42.0P@)3!^/4`/2^MQ09\APWSO
MV<B/3!F\ZX&_,KFO%:/3_>^ACJ0.`].GM'WC^GDPR9><I%.X3IAL'@O>/&?>
M`T3H2^6\EU>LDQEM_K5#NVL=9=@,(%;-V1YB@'<B@S?Y)K,8U1]V9K&`79V+
M7TP,)#%.5LOZGWJNW).UDDI9<\'Q#96[8OZ[B7,V/<CX]S-6I,"F]Y@)+&\M
M5OUZ1FFRH>02QA7Z2I_^"4.`@(A1^OG<+D;!&;7[?Y]J^8<'Z@L[Q0\=ZLPV
M0,3V]M>+]!058?N;3E.*QY$5M_D4J>3;A)BVCF[IH00;1J1A`@J''@1M?MP\
MHX\<ZYY_U.RQ4,@5+).4MG-E,G(XORIB#)-41MF'\DMHM=%T>5G:JWK"J+J)
M*X;O&BCU-=,>I!3$QNG`^?;IN-_[-NVNP';2SI4,NS.FUUM[[-FD>=Z[C6_9
M'J=3A;Y+&_5,67!]28&PJUPK>0,*?J."D2;/VRBBGE2>IG`/V=_C/=0F\O=O
M&E4F$RADVWZT;TXRS=FN'QGB#)EU+0<=0#-D]>RLM*0=8=0J[I1E(%42:MG*
M[DY2'ZD*)>@ALC5&Z8QV5Q0:?KC@UOQ;DB#FX,_ZI7[!7AF(20(\@9Z-DH&U
MQ<-.L@5)ZR"A'#1(W0?9T\>!K:Z32ET[!>3<O:A[/P5WD^W/D+(DUE#5/;ZM
M5>QW>H8J>6@R!9G$6<VM7CI>7HIP*@@9"25;A'J.R&/Y_3<&,@$IV3^ZEB&W
M5F0I^A9QW<V0L\:>.QS1\/MY&4H->FY1`Z,;;LT97.R)1,94*OK'!U('>._U
M!5)(46S958X``?ETF[5&)L%Z2735W8R/KVPE@V5LECRMN+,3#9Z%?R[E6]RC
M6P60J:0+-9$M5A'C5NTC2**%5%!J50P%,<Q0"ZF".TCVVM8LG0>9L!:>8>Q=
ME&M-9=E!72LQ,BC,1C2?AW<!--VQW4FZ;@E)PSY9NL`IB!TU!Z^(]>!$AAVA
M9/[$&S^?"IXTR%EGM1[17EWE>+N&**Q*7^W:996DE!1G8V\8_KJ#ZT/L32;?
MR()R4<V<>ZMVS<5"@9,Y#A([?^]7H)`T>1L&*\O#LE?UHYT-)P;@2HW;(.7K
MU8Q;G&+K32HQ-=4D:ZN\>>5-5Q*D9MVA?,94Q?+TX$:_<JSUDR1['-QP=LA$
M7^7WVVBP6RE@P=6,<VJT6R*G+GDYE9?Y9?HTB`EX2%8XXK:0,5U'3@IP"/'S
M"<YO$,PM$^YGJG0=*]7*3EB6R_B/(&/,%8XH5TH]VULV*;SD%8J/4HBO3*2I
MX_%,@Q<LUG4>91NJBL<BJ)RCU\W@`8R;P=P6&SUVM]^9FXQ%DH\7GG_.;"&D
M>-9+%F0XK,N7:Y4X.M5MU;W-*<PRT^DE:[O(/G;+WAHR(WB"HG5'S&,(!5?:
M7[G>K>*^W9JSB;-S_+F'<FX?Q/7\<W.J7#7#88RB<O6RKL"O8F3A,8S$3,QD
MDU1372.@N8W13RF*4P"'`Q\[E'<:KNT?;0[BU>1BK9#0^77RV$M)L=O\/Y-A
M\PYH8THV.U,CY%&IO8(TTWJKVX2CQ*.7=,X],C..$Q_,=0`X&7_;H[JVHU(T
M/U=I.69?+F)K]C'"&/,<7"E6_6[8DTHQL-(K3&NOO=',-BZ4C)5F]4C/604;
MKG**:A>O0>H`$BVA>TUGW'I>6LVJ567IV(G6:K52]>X^U4NQ46ZS^,:/&P<*
MXOEFA+01I+MOYQNI91=@DJT:'3C2(>8@F$3"&=G`<!P'`<!P'`<!P'`<!P'`
M<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`BA[G&BURWRIK*@Q;##Z+2)K<^^QGE*
MT.[K5<R:U9]*[:FI6><.W*F,G4@]_0HTJI9"".M'(R9T4"*.!1,J4`PMC>U'
MM[$YZG+LIFW$UNH3BT;CV5H_L$]E2.OUA':O6O'^&TF5GAHZ+>5=@2I9`I[J
MPC[JX.F8\DJ9$$U_S&"WA^RUL]%T]5G`9>PDUNKG370[`$O;U7V4T9.>MVF]
MHDY"YU22FXYBC828;V/KKENSF'";@DLU,V*!F[HO4#!(GG/1G(F2>U_.Z,8^
M<8UH]PL-3A*R1W+7')]PQ_4?=;_&W:2:Q]ILK&7R-96#$&9V;0[M-NH(&+T3
M03(1(H6'VC[6V7MD-S*'M4;(U"J$M5&VM#2HV:+6L:%SPU`XPL]HE<]4>+AV
MT,G6<WP&>X*SG9LWEF,U=55P0KEF0#`(&#&Z.[&&30I54@9+,U"5F-:L4X)Q
M%JZZCV-F"'G(K`>X;S;&%LN:6BC8#-)*Q-F\;7'36-"0*@9!9\"B@J@B0)C=
M$]9+%JYCC)D+=;!#V._9JV-SULU?5ZTE()U6'LN;[V\M0U2K'E$&\@]AJI$G
M:L"NETT%GBJ*BYDD_4\H!FYP'`<!P'`<!P'`<"-SN+:>WS<1+4V(JSK'J=;P
M7M?CO8:_Q5]EK=$C;Z]1(VPQAZ?`.*BQ<N&TG*%LBBH.%E$DTC-R%\04,)0C
M]R%VE\\OMFY*[423U\5UC8XPS!A6MX9M-IS7%SDIC[*N*:!3X]I>;(V:VJ3D
MU<=V^GJOXQ!L^;LT4W":[5-J_!9RL%^-#>WQL+K#8-=QRM9\*Y&;X+JNP-,D
M<K0=DS0GE[)4;D:8IRF/YZZPKR0C,9S=LCJ]7083CU^S?K`1LW4CCMO.L0P4
M1L-VXLE9X+L)AI^RJ-CQ#?\`>:F;G/XV[24U`0V6J8^QI$U&SXA_S#I[:1OF
M)+Q0<@55O+QTK&MC&58D;H"8$E7(`%Q,']OK8?%%N[8LO/92QSDIOHGAK/&,
M;W.2@V2#LUW4RY$1E=K:579,JZXCEHV@0<"U9"[D%DG4L5(5U")K&,(A93)_
M;\SY=9?:7+K"H5+$%OVVUE;:EVW#>.<CV'(=$G[I=,B.'5BVPRG8['&UQL>1
MQECU=9"#*@Q-(^D=5NH<?,@F`9`]S?MPVG>RGX-I<59*4XJF)J_EA@M`7A[:
MJK+*7NWXT)1<89DKF0J+&RUH:2^*I85WJ]?.E^D61!X9)Z8`22`0\"=[<DY9
M<WZK9=D:[1V61]<X&#:9KV.@W:5=R=NXPBL(KXQDL4W>A0,>TJ,;C2Y23LCB
M0+/.)`&*31%!HW3*8ZI0][5_MO2^&[#L58Z=<+#IG1<\7K%5KK6O&K]JAI"H
M8S3QQ7)6*L:Z3V[T>9J<5*Y>>RJ:TXUKT3'M$DXUJ5%=14RRI@IRK]NG.N"=
MULB;6X7RX:U04OJ_=,35FN96M@2UIE<LWG)[[)CB[7E\PQQ&M92HQTU)"H#?
MWXTB862*?JF0(FB0*@WJ[73[974$,"XPRI.UG(47CZTT^&LEOGS%I4_8LC2T
M1+Y+R=D"*1J=LF):[6%PS=B#EJ=LNFG)ND"*D064*8/2@>W_`";S<[`&T3*L
M5?#UDPA"3S#+F5*?:EGF2-SG$WB]GCYI"94AX:MUBLNZ?"2"9)4'LJDO,^]Q
MS0K9)JB97J$$W[Q[H%`[?XC^%^S[X?Q`:ICP#!_:01XG=KQ;3ZINOV]I"$[.
M>D0D(!`5HER<"4OC^9?+%^5./]8F./"C+SEK%_O""B?;S3X?*;R*:X6_Q%,P
M^H4F353*ID$?R^<I#AY@$#>!NG3J(<2G#S]F)],[.-LW*[+^`]V=<XN0L&QF
M*'>9Z]DBAD6?OY+,N**?D.?1KR54(]=N`1MF-XI)1%BQ1*F1_'B9`I?72;]8
M:.K2W3.S7`_,!CD.0Z:B9SI*I*E%-9!=(YDEVZZ)_*J@X;K$,10AP`Q#E$!`
M!#ATWU?V='^H'>'_`*<L9C_HQNL/)9,OR2VZIO*./ZY=Z7C><L\=&WK(K:>>
M4BM.!6"1LK:K-$'UA6C"E2,DL$.S<IJKAYP,0AP'IX\*U-VS+V$JG=%JC<;;
M48F^Q^/9W+`0<KZ(6,<<5-TDRL=PCFQD#O'T17G2Z9'9FWJ';"H3SE*!RB(?
MNMV;L54*A1V4;A<8V`H,NA%N(VSO4GHL7B$RU._BU$2(-5G9B.V"9EP_P_R(
ME,<_E*`B`*%F_%64*8^R)0+G&6FDQA'2CZQ1I'@L6Z;.,;S2ZABKMD7)T_TA
MVDY3,5,Q5D%2'3$Q3`/`^&+<[XDS6T,_Q7=8ZYL0B(6P$>1C>21:N8*QINE8
M.:8KR#)FE(Q<F1FKZ2[<54S"00Z]>!^*M[%X0M]_EL65W)59DLAP<K/P<E4B
M.E&\PE,U5NP=V>*10=HMROI"O,Y1LN]10,J=L@X34.!2'*80]RR9FQ;4+8G1
M+/>(&$N;BDV7([.KOW0I3<C1J:JT1M=DB8\"&<2S"O'?H"\]V!51`JR8G*`'
M*(A5+&QUNPU1E;6+]D_J4U!MK"SE5B^2.=P#QD630DC@\32\C-5@<%NJA2]"
M#U$`X%.1]]QJSQX7)L3.5TF-'%=+=$;?"F:*5QW6%8XLHG8FSN.*9%W'K1P@
MJ11,#B<HAY>H^'`IG%NQV$<V/9J.Q7D.%NCVN"J$ZVBTY`BL8+>2>PSDKDKY
MDT'SM)>.7:K%+YC(N$Q(<"F\.!6-)R?0LCKW%K1[/'61QCZVOZ'<THX5C&KU
MQBVC-](5Y_ZR*0%D6C2104.4OF`"JE\?'@4[7L]8>MUR=X^K60J[+W)FXGF9
MH1HZ.*KIY5'2#.U,HIVHD2/FWE7=.")R2+-9=1@<WE7*0>H<#\\YEW"6/[9-
MU.>ME/K5WB<=RN6YB`4!!K8O\M(5X+*;NA6+=O[])042^+Z;I5`JWH',4#@'
MG+U"XR-IKZU9)<22;9.KJ0H60LVN)FK$((6/ZF,LJHY*D*#0L?\`XQC*`42D
M`1$`Z<#[0EBA++`15JK\FSFJY.Q3*<A9J,<)/8Z6AI)JD^CY./=-S*).F3YF
ML15)0@B4Y#`(>`\#P<?Y$HF6*Q'7G'5CBKC5))201B['#*>]1SM6,D'43)IM
M7(D*)C-))BJ@ITZ=%$S!^'`J.9FXNO1<I-S+Q./B86/=2LJ^7`_H,8YD@HY=
MO%A*4QO0;()&,<0`>@!P*`6S5B9'%09W6N]?)B$M3"\#DD[CI6$J6=L5\:SJ
M28D\J,$5D(+G<&`$RHAZAA`@"8`]N`R51+5+/(*LVB)GY5A`5RU.FL2Y*^`M
M:MZ3EQ5YU)RAYVCF+GT&BAVJJ2ARK$((E\`X%(.-B<)-;^7%JV1ZZ%]-/-:J
M->367763M3Z*4G6=67>H(*1;:SN85,79(Y1<CP6_0_I^40$0O.`]0`>@AU_`
M0Z#_`&@/B'`YX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@
M.!'!M3M3>JEM1J/I)B)2%K.0-JHK-UXE,J6:,-/-<=8XP17H25L"E:K"RC5C
M9[Y9)2P-&C-%VL#1FV!=RJ17R%((1V5CNB9Y5VPQ]K+DN5H53/A#=O.&N.S]
MYBH1NUJ.4,753424V5QMDN&4F'CQ?&LDG%`D:R,45UTV[EN?TE`14*F4+GX_
M[P&,`V7V-E+]?9..U*;T;2@=97+O%5C@9^ZW'9E#*3I"1B!?Q[>P3U>OK2G-
MG<.[>)M&HH`)$Q$YTRJ!DA;N\EHM2+'D.K6*WY1;RV,9C+$#9P;8(R[(-/U?
M!=>J]MR\QC7K&I+MWZV/ZM;V<A(@4P>DS$Z@>8I!'@70R)W.=.L53,I#W#(,
M\U/&X<NV=2R;/'EZ?P<Q0<=T*OY1MR]>F6T"=E/RT/0+2PDU&K4RAP1<>3KZ
MJ:J9`R8P]F6J[%XCA,KXQ&VQ-<NT2]=U9W=J-8J5.$3`%$6<LXJ-P80\N5DH
MH!5VYE$B).T!*HF8R9RG$-::'[M6Z,]H"XV\C+SC$U[BW5?:6K'$EKK<HJEQ
MPV3<J,UGB7M6R"]FFL/<$U(%5[(OD&RZZC5\1N'F](YP$-G:]3=@J&.YF6C'
M$8^LT#!^J5W+1<\ZC'#Q%-`KN04K]10D;#(D.'G62CV!#N5C^5!,Q>OG`(-G
M7><:Q.C.1,OY+F<?4G/=4R9GK'$Y6*E'3+.=QU5<*6M".L&0[/B#*3Z/M,5>
M8VCS$6_+4W#AT=66EV38%3I*+'2"[$?W.%LK;/V3#.,;U2Z17*Q<G^`L,2]V
MK\W*PVVVU\=AB,RM-X_<9`KT3+5#&5%J,/9F"O1!<TY8G*#T&`%0;?XH>LVV
M'[H85[.UCE$.W'&UG`\Z:)LF1EW6RXTY\XK=;6F,B1$/']/UJ1E*O)KL8[_#
M\J"K\'#<H'63\O`DYURG,SVK!^,+1L'7:?3\R6&JQ\W?:G0E)M2JUN6E`%XG
M!QJMD.I-G4C6*R1'/K]!]Z*H4`\H%X%\.`X#@.!B=L]NM@'3Y7'Z>=9RR5XF
M3W5M84QU$4>UVIA)2='J<G>[#%+R%>BI!G&2B%0A7K]!!R=%1XDS6!N"IR"3
M@8P3W>9T)K-:K-UE\A7E&DW.E3^0ZI<D</9.=5:P56IXZ@,M6IY%S;:LJL'3
MZMX]M#*2?,2G]^;I*F(9'U4EDTP6WO,:#T1;R6C(MRB61ZTRN;2;5Q)D@:Y*
M5-[;*M1?YAA;`2N#$346QN%TC(]VHU66]S7=E%;R$`QRADM+[N8"B:)0KVI*
M6U\AENYV6@8FJ<50;7)9"RE9J@G/NK`VH=(;1AIZPL&$55G[X7J27N1F#85R
MJBF9,3A8P.[-INA*7:->S>6(MKCO+5*P9<['*X'RY'5*O96R%)UZ%JU-E;,Y
MJ1(F.E'DO:6#=8'"B16AG!3+BFF('$*HJW=`TVMU\@\=Q^0YIA-S]XA<8MG]
M@H-TK]799*M,#/6VF4*8M4K"-H*)L]UJ5;=RL2@NN0'K$I%"&_QD0.%Q;5O?
MJ_6+-&5)ED9M?Y=U67=YES8FCWV4HNE8[CK`A5I7(5[F:.C-1=3ID1/K@W=/
M'2I/0$BAS%!-)4Y`CFRSW38W)64=0&.G&1$)/'N3<B;"TG*;JP8VEFYI0*II
M_>,_8FF:P\M#"/*O7))[#,WH.&'G*[;F]$YDS^8@AD]JAO(P<=N_27939ZT`
M[R5LECG$"3=C4JHZ>3>2<RY+K:LXVI^/Z/66KMT]E7Y6;M5)L@3TT&C9154Y
M$TSG`*_A>YCJ'/WF.QTC>+-&V:3FYNF-DIS&]]AF),J5?&B&8;1A9U(/Z^BV
M:9BKN.7(23NOJ&*^3`ID0*9P4R0!:W&O>,T3RM+8]AJO><A(.<H3&&(:HN;%
MA;*=<B7)MB"3A<)2<A,2M6;QD3!Y)?UQVRC';A5-)5\EZ(B4_`E.X&E/^\A\
MW^7V@`E#S#_/V??#J4`\:KCLO4QC&*4H!U_$0\>@<3NUXMI]6=?8G[CNA^,N
MUEJGBS)6V.#<<Y#QW7+;6;C2[]?X*GV.#E?\Q;=)(IN(R?=LG"C1XPD45F[@
M@&1724`2F'H(`498TNN;W$TNQ3W-:Q1838_=/`C>8QI*/7])OF/MB:!6;G",
MID&9+#`!(BYD6KJ`G4V"0JH+(']-=,BJ1B'#J)S6TTG6&7.NVXG9_P!5<+X\
MU]P?M_JE3<7XO@TH"J0*><J2[630!91XZD)%^\FU'<I,2LDX4=.G*IC'7<JF
M./X`!,WM._BU#OW`.JG;XN]@L&\>B&TVL$U;)Y^F\V!U\I.6Z0N_LTB^<%37
MRQC.!8R8@YG5C*$&<C$2B+D1]\1**GKE-$M-)MM:)26_LZ.HZ_[Q^;H`_P">
M.-B^`]2^&-UR]0$WMZ_[/#DPSY?DELWY6Q3?+5M5JCE6$81BU&Q##9^C[JZ=
M3!6DJFYR;6*G"UT8J(!DK^H@FZA5!<G]9($DQ`0`?9PK64W5U*ONQM@6L6/G
M\90\C4'$\N;!F7W3\JRM:R@]D7S:6J%AKZ#0KZ2QED2GO5HN?("YB+H+`8J?
MKMT#E#*FXT2P2VNL_CR/8Q;FY/<*R],C6ZSGW6.3M+N@N:VW$DHL@HHS8^_.
M`+[P!#'*CU$`'Q#@?DP]CRS4O5S'&-YV+C4[Y6<%U&CSS%A()+1SRV5W'D=5
M7)4YD&S<'#-9ZP\J;DR91]'RB(``=.!8C0S"F7,"8TJ6/<CQ3QJ:KX?Q74'S
M]]E97(D<K:J;$N824;4.(-$L?Y2IQ$$RN"IF,!W"RP!Z*8IF,<+(8QU#SA2-
MT[#L9.HU^S4*?S5G&8B:C*7)513&\'DFE4*$ALQ4)BWA6K5.YS2=3=0-CBGJ
MKD/TIRW7:+$43735"[NX^L%WV*L41+TE9A1KYC3'5FF,&9K.];+NJ)FAW)L"
MMX.3KH(IR,OCN[U=-Q$V-(JWHO(QT8`)ZZ:"A`OM?*7DV3UUA<759-@UMTM6
MJ+C^U/V\@U30KL`Y3AX7(<["&E&R[6:<QT`5X+%JJ"8.CG(!S%#KP*)TLPM?
M<#8JMF#+XT@Y.BT3)MZ9X/DF:D<I^J82L$J>U56&EZ\T:H,:XO3W<T[B&[(H
M'1+&LVIBB'42E#U=0L7WG%=*R'%Y"@HN(G+%L#L#D*%"/EVT]YJ;DK*=@O%:
M*Z?)(-Q:.@8S)/>&H`8J2Y1_,8>AA#]VK^-+]CF5V<=WB(CXMMDW9V\94I@L
M)E"8.\I]@JM$A(Y>031;H_I<D+JLKF4;F$XD*8OB/7@8GX<U#S%59'4FB6-O
M6XVG:A96S?DDF2HNP)O)_*[.^L\E0U5B$8$K-%_`+R+3)QW=E%XJ9)1U'%*B
M9?U0.F%6[HZE9#V+M4A:\;K15`R=0L0JHX&S(_>H.B1M^D92P,KCCRUUM%$)
M)[C+)%'EQ82Y14%,_5-8I/7:HFX&4&8J+?;3A*/QA3TVC:3L[>FTBX2AWC,R
M==HKA2.:W^39LY-(S2Q.?T%LNU29G\@.?>.@G('7@49I5BO)N!<,.<+9`392
M$9B^[WN!PY-,7C`R\_A56<=S&-T96-8(H-*S)UZ)D?T<&)?.D@V8H"4X^80*
M%G]9XS:#7;`-0QO,X'@I]S1D9XSA:)RG#.7-AD;EF1W($2A"(PQDVC2OTZQN
M9!XJ\],5UV@-TP#S>KP,Y\BL)2>H%\A(5L5Y-2]/LD3$-CN$V23R0DX1^R8(
MJ.UO.DT34=+E\RA@$"!U$0'H'4,9:CB?(L#H94\&2]2A)3)<'KA6L72U4">C
MG%=D)Z+IK&K2;`]@?L!C7,&\%%0PBLV%-1`1(<GYNG`\W4'6:WZS3V6JR>P-
M);"KXU)#7NM**KNI_%M*:H6.4F\3/Y-7S$E:S2++8G"5;5`WG2AUDVINH-2B
M(4GAO%V<<"*YGJ2&)ZAE:"L&Q63M@*/=I.^Q4`[?)Y/L!K.6&F8V2A)22C+O
M37;Y>/;/R`=FM'()"50AO\/@2'MS"9$@BGZ0]!ZD\1`!ZC[!'IU*/X#P/OP'
M`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<#'+.NJ^(]A)G%
MMON["<C,BX0L[^WX@R?2YY]5K_CV:F(U2%L(0,ZR$Q5(BSPBIF<G'.T74>^;
MCY5D3"4HE"P:_:_U!>K5)U)4NP2LA6\DY<R_-RDE<9QW)Y/R-G2B.\8Y1L^6
M'RB_O%X=66@O3Q0)KB5NR9@1-JFB5-,"!9EOV4=)TJ;:L>O"YMG*5=,<XZP_
M8JY9<SVRQQC_`!3B9E88K'=!,A-'>^6#J,/9G+6/4Z^^L4RI';KI+I$5`*KF
MNS_IA/.[6\?0V30-<Y;/4S-H-\IVI!`[O9:A5S&&7B-R@Y%1%M8J+4HY@F03
M&!J1J51+RJ]5!#P;SV9=+K[8):T3J>:0F)[&[_$,FNRS/<$45L=S6'H7!EBK
M*+=9=R@QC+#CNMLD'B:!4B'=(>]%`C@ZJAPREPIJ77\*6_*MFKUZR*Z99+H6
M'\;-:_(6B5>LJG!X7I3RD5^>B?U-X];(767BW9"OW[5%JFY]S;&.D94AU3A:
M@W:[U8/ITST2.VR:;71A;T+HSKO^9UE+8&\HVOG^9[=JG;R+%GPB$<@@$L5M
MZWD]Z#_>?DX%]&VL49#TW(=9KF8<]0MER)8:]993*BN1CV/(T4\K9(5"+CJ_
M(6R-FX*+KQF,+[LXCRL/=W"+MR)RBHL8_`M):^VIJG>\#9;UZM]1E9NJYZME
MKOV9K2XF"HY+R%<[V_9O[?8):[-6B,E&.ID(QHV%.,!D@W9,T6Z!$DB`7@(?
MMK:KUS*#/+L%6K%&66-N$3E1C%)6=^:D-LW0.+E,-1><R4DP!`)Y1;X[/[B=
MZ1(C=82@NH@9P`*\"^*6L^.$\:8SQ(0TZ>C8WM%;N'Z:M(IKFO4[5Y-Q8F[C
M(3A1`1LH2MT6+-OR&\A7DFB513J7S$$,B2B`E`0'J`@`]0\`'KX]?[>!SP'`
M<!P+%9_UKPQM!6*K3LX4IA>:Y2\E47+=>C)`RI$6=XQU,IS=9DA,B8BBJ"3D
MADG#<P^B[:K*H*E.DH<HA8='MJ:6)XHPYA%3"5>=XQP+EJ7S9C&K/E';QC!7
M^>>6][+/5076.:2B7QKP_24CW'J,CMS)HF3%)%,A0IR=[56BUFQ5A3"T_@^(
MEL=Z]4'*&,\5PKY_).#0%1S%57M/OC%9ZHY,ZE%Y&,?&616<&44:/B).D1(N
MDF<H?"7[7&K,DVK:;`<P55_0;M0+[BF<J69K["3.&YG'F+6>&H]GB=TE*J)T
M>O6+'S06<Y'M$RM)A1=5=R0ZQ@4*%%YD[<E$E\'9WUXQ]$)6*C[F9L:9"V<6
MRW?;/*/(N-E48).Z77'!FD<[?GOGHTN)3CFRCEHV3=$*Z,L!DS%5"[#CMKZD
M.<QLLU?R"_1F6EOQ[DA6F-[)+IXOD\G8HH+_`!=CG),K0A7-#O+A5*!)'C$%
MQ`$54B)'7256234*'KW7MZ:O7')M6RNUILGCRR5['L_B&7CL26&2QA3\C8DL
MTF:;F<99/IU//&5ZYT]S,J*.@070*J1150"J`10Y#!;FL]J_6"JPF%ZZQDLW
MOHC7>5O$AA1I.YJNTX3';"^X[EL42-7K_P"I/7`(U6)Q_..HZ-9G\X-$EA,!
MC*%*8H>.U[1^HS#'=6QI'FS8PA,=DP8KB60:YRR&G/X9E]=6,]%8QLN)I(TL
M<M(LC*)LCMI(.VB8'EFQP3>`L4H!P*NCNV!J?&9&<900A+XM8W-RL.5!0D,C
MVF3ADLVVW%HX:LV=$HU^\<%#+,YCXPLUY,QC$%4PN2HE<F,J(4%5.SSI?2PI
M)(")RBU3QZ?6Q2K)J97M:Y&0ZDS4[8,$E6!5R(O"5&4LCPYP5$WOH*^5QZA0
M``"4G@1$]UCM$XT[KL)A*"R7ER^XI;X0FKM-Q"U#BJW)K3BUWC8..>H2@V%J
MN5)%B6"(=+T0*(F./FZ]`X71EBNT(:C?L[-5SCU/M[L&8?#Q-5<:F'P\`\1C
M!]G"N]NN=77_`,'3JI_VN]@?^2>-/A?#D_\`!TZJ?]KO8'_DGC3X7P.0_9UZ
MJE$!#;O8$!`>H"%4QH`@(?B`A%^`\C1?WY\DU7:H[3F..U)3,Q4G&V6;WE9A
MF2Y5VY2KN^1=>C7<*[KM?-7T6<:%?;H(K-W2)@4.*H"8#!T#PY*JUNJW4EBX
M<G`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!
MP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!
MP'`<!P'`<!P*`N.3\>XY"/-D&]5&E$E3+IQBMJGHN!2D5&Q2G739GDG;<KA5
M`IP%0"B/E`0'@41]S^N7SXP_]0ZM\4X#[G]<OGQA_P"H=6^*<!]S^N7SXP_]
M0ZM\4X#[G]<OGQA_ZAU;XIP'W/ZY?/C#_P!0ZM\4X#[G]<OGQA_ZAU;XIP'W
M/ZY?/C#_`-0ZM\4X#[G]<OGQA_ZAU;XIP'W/ZY?/C#_U#JWQ3@/N?UR^?&'_
M`*AU;XIP'W/ZY?/C#_U#JWQ3@/N?UR^?&'_J'5OBG`?<_KE\^,/_`%#JWQ3@
M/N?UR^?&'_J'5OBG`?<_KE\^,/\`U#JWQ3@/N?UR^?&'_J'5OBG`?<_KE\^,
M/_4.K?%.`^Y_7+Y\8?\`J'5OBG`?<_KE\^,/_4.K?%.`^Y_7+Y\8?^H=6^*<
M!]S^N7SXP_\`4.K?%.`^Y_7+Y\8?^H=6^*<!]S^N7SXP_P#4.K?%.`^Y_7+Y
M\8?^H=6^*<!]S^N7SXP_]0ZM\4X#[G]<OGQA_P"H=6^*<!]S^N7SXP_]0ZM\
M4X#[G]<OGQA_ZAU;XIP'W/ZY?/C#_P!0ZM\4X#[G]<OGQA_ZAU;XIP'W/ZY?
M/C#_`-0ZM\4X#[G]<OGQA_ZAU;XIP'W/ZY?/C#_U#JWQ3@/N?UR^?&'_`*AU
M;XIP'W/ZY?/C#_U#JWQ3@/N?UR^?&'_J'5OBG`?<_KE\^,/_`%#JWQ3@/N?U
MR^?&'_J'5OBG`?<_KE\^,/\`U#JWQ3@/N?UR^?&'_J'5OBG`?<_KE\^,/_4.
MK?%.`^Y_7+Y\8?\`J'5OBG`?<_KE\^,/_4.K?%.`^Y_7+Y\8?^H=6^*<!]S^
MN7SXP_\`4.K?%.`^Y_7+Y\8?^H=6^*<!]S^N7SXP_P#4.K?%.`^Y_7+Y\8?^
MH=6^*<!]S^N7SXP_]0ZM\4X#[G]<OGQA_P"H=6^*<!]S^N7SXP_]0ZM\4X#[
MG]<OGQA_ZAU;XIP'W/ZY?/C#_P!0ZM\4X#[G]<OGQA_ZAU;XIP'W/ZY?/C#_
M`-0ZM\4X#[G]<OGQA_ZAU;XIP'W/ZY?/C#_U#JWQ3@/N?UR^?&'_`*AU;XIP
M'W/ZY?/C#_U#JWQ3@/N?UR^?&'_J'5OBG`?<_KE\^,/_`%#JWQ3@/N?UR^?&
M'_J'5OBG`?<_KE\^,/\`U#JWQ3@/N?UR^?&'_J'5OBG`?<_KE\^,/_4.K?%.
M`^Y_7+Y\8?\`J'5OBG`?<_KE\^,/_4.K?%.`^Y_7+Y\8?^H=6^*<!]S^N7SX
MP_\`4.K?%.`^Y_7+Y\8?^H=6^*<!]S^N7SXP_P#4.K?%.`^Y_7+Y\8?^H=6^
M*<!]S^N7SXP_]0ZM\4X#[G]<OGQA_P"H=6^*<!]S^N7SXP_]0ZM\4X#[G]<O
MGQA_ZAU;XIP'W/ZY?/C#_P!0ZM\4X#[G]<OGQA_ZAU;XIP'W/ZY?/C#_`-0Z
MM\4X#[G]<OGQA_ZAU;XIP'W/ZY?/C#_U#JWQ3@/N?UR^?&'_`*AU;XIP'W/Z
MY?/C#_U#JWQ3@/N?UR^?&'_J'5OBG`\;./\`P5<_]IDO_1-N!C]P'`<!P'`<
M!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<
M!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<
*!P'`<!P'`<#_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
